Opendata, web and dolomites

RIVELIN-CLO SIGNED

The Ultimate Therapy for the Oral Lichen Planus

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RIVELIN-CLO project word cloud

Explore the words cloud of the RIVELIN-CLO project. It provides you a very rough idea of what is the project "RIVELIN-CLO" about.

olp    approved    generating    clobetasol    erosive    corticosteroids    perspectives    spread    treat    share       burning    causing    rivelin    disorder    84m    daily    company    mucosal    occlusion    tissues    prevented    lives    markets    venture    innovative    2h    bystander    22    international    mucosa    founded    therapeutics    10m    clinics    saliva    clo    minimization    painful    ways    goals    financial    patch    time    drug    launching    patients    correct    chronic    commercial    diseases    usa    exclusively    staff    alleviation    involve    sensations    living    cure    normal    ongoing    toxicity    guarantee    6m    oral    kept    first    clinical    ultimately    employees    lesion    therapeutic    trials    lack    options    struggle    revenues    symptoms    incorporating    2014    primary    undesired    efficacy    potentially    lesions    launch    combined    market    generate    planus    damage    systemic    gather    electrospinning    lower    lichen    afyx    worldwide    people    treatment    dosing    hospitals    reg    ip    danish    precancerous    iib    immune    adherence    suffering    self    chance    topical   

Project "RIVELIN-CLO" data sheet

The following table provides information about the project.

Coordinator
AFYX THERAPEUTICS A/S 

Organization address
address: LERGRAVSVEJ 57, 2TV.
city: COPENHAGEN
postcode: 2300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AFYX THERAPEUTICS A/S DK (COPENHAGEN) coordinator 50˙000.00

Map

 Project objective

Oral lichen planus (OLP) is an immune-related disorder affecting 84M people worldwide (10M in EU and USA). OLP is a chronic condition which can ultimately lead to precancerous lesions, while patients suffering from it may struggle daily with painful and/or burning sensations in the oral mucosa, being thus kept from living their normal lives. Since there is no approved cure for OLP, the primary goals of its treatment are the alleviation of symptoms and the minimization of mucosal damage from erosive lesions. Current therapeutic options involve the use of topical corticosteroids (typically Clobetasol). However, the ways of use available in the market show lack of adherence to the mucosa and there is a high chance that the product is spread to other areas (which results in reduced efficacy and potentially causing undesired topical and systemic side effects). Our Danish company AFYX Therapeutics A/S was founded in 2014 with the aim to develop innovative approaches to treat mucosal diseases such as OLP. We have developed our first product incorporating an innovative technology (using an electrospinning process): the RIVELIN®-CLO patch. It’s the first to have been developed exclusively for the treatment of OLP, and its unique properties include self-adherence to the oral tissues (2h of topical drug application); occlusion of the lesion; lower bystander toxicity (Clobetasol is prevented from being spread by saliva) and the correct dosing every time. Clinical Phase IIb trials of the patch are ongoing with clinics and hospitals across EU and US and through this project we aim to guarantee that RIVELIN®-CLO is a success from a technical, commercial and financial perspectives, before launching it to the international markets. Five years after market launch, we expect to gather 7% of the EU and US combined OLP treatment market share, generating €22.6M revenues to our company and increasing our staff to 40 employees and generate new IP to venture new markets with our technology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RIVELIN-CLO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RIVELIN-CLO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  
lastchecktime (2025-04-27 0:24:02) correctly updated